Proteomics in Small Cell Lung Cancer (SCLC-OMICS)

Aalborg University Hospital

Status: Enrolling

Conditions: Small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05623956

N-20220023

Details and patient eligibility

About

The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.

Full description

The study will include 50 patients with newly diagnosed SCLC, referred to systemic antineoplastic treatment at the Dept. of Oncology, Aalborg University Hospital and blood samples from 50 healthy blood donors.

The blood samples from SCLC patients will be collected before chemotherapy with Carboplatin and Etoposide and after 2 cycles of chemotherapy.

Imaging will be performed at the Dept. of Radiology, Aalborg University Hospital before chemotherapy and after 3 cycles of the treatment.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Written and signed informed consent
• Histopathologically and/or cytologically newly-diagnosed SCLC
• Measurable disease on CT scans
• Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide

Exclusion criteria

• Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
• Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
• Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
• Treatment with any other investigational agent